查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020272

酵素替代療法市場規模、佔有率、成長及全球產業分析：按類型和應用、區域洞察及2026-2034年預測

Enzyme Replacement Therapy Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 150 Pages | 商品交期: 請詢問到貨日

價格

酵素替代療法 (ERT) 市場的成長要素

受罕見疾病、慢性病和遺傳患者病率上升、醫療保健覆蓋範圍擴大以及先進治療方法方案日益增多等因素的推動，全球酵素替代療法（ERT）市場預計在未來幾年將保持強勁成長。根據近期一份市場報告，2025年全球ERT市場規模為158.9億美元。預計到2026年，該市場規模將成長至173億美元，到2034年將達到356.7億美元，2026年至2034年的年複合成長率（CAGR）為9.46%。

酵素替代療法是治療方法，透過向酵素缺乏症或相關疾病患者補充特定酵素來實現。其廣泛應用主要是由於溶小體儲積症（LSDs）的高發生率，例如高雪氏症、法布瑞氏症和龐貝氏症。例如，2020年美國約有6,000人被診斷出患有高雪氏症，據報道其中95%為1型。

主要市場促進因素

酵素替代療法（ERT）市場成長的主要驅動力是罕見病患病率的上升、先進治療產品的持續核准以及醫療基礎設施的改善。 BioMarin、賽諾菲和武田製藥等主要企業正積極推出創新酵素療法。 2019年7月，武田製藥在印度推出了艾杜硫酶、貝拉格魯塞酶α和阿加糖酶α，用於治療韓特氏症、高雪氏症和法布瑞氏症。此外，已開發國家優惠的健保政策和意識提升也加速了酵素替代療法的普及。

在新冠疫情期間，酵素替代療法（ERT）受益於相關藥物銷售的成長以及居家照護治療方案的推廣。自2022年以來，藥物銷售的成長和患者對先進治療方法的需求推動了市場的持續成長。

市場區隔分析

藥物類別細分：2026年，帕尼酶以24.13%的酵素替代療法（ERT）市佔率領先市場。這主要歸功於其在治療慢性胰臟炎和囊腫纖維化患者的外分泌胰臟功能不全（EPI）的應用。阿加糖酶位居第二，反映出其治療法布瑞氏舉措的高成本和不斷成長的需求。諸如mAbxience和Biosidus於2024年達成的阿加糖酶BETA生產合作等聯合項目正在推動市場進一步成長。

依給藥途徑分類：預計2026年，靜脈注射途徑將佔市場佔有率的75.87%。這主要得益於其諸多優勢，例如藥物可直接進入血液循環、劑量穩定性佳，且適用於胃腸道疾病患者。由於溶小體儲存症（LSDs）的口服製劑選擇有限，口服給藥途徑的市佔率仍將保持較小。

適應症：到2026年，外分泌胰臟炎（EPI）將佔最大佔有率，達到24.13%，這主要得益於慢性胰臟炎和囊腫纖維化患者的高發生率。新興的罕見遺傳性疾病和溶酶體貯積症正在推動「其他」類別的成長，其中包括用於治療2型神經元蠟樣脂褐質沉積症的Brineura等治療方法。

按最終用戶分類：預計到2026年，居家醫療和輸液中心細分市場將佔市場佔有率的69.23%，成長速度最快，因為患者出於便利性、成本效益和安全性的考慮，越來越傾向於選擇家庭護理。醫院仍然很重要，但由於容量限制和對專業基礎設施的要求，其成長速度較慢。

區域趨勢

2025年，北美市場佔主導地位，總市佔率達75.7億美元，佔全球整體銷售額的47.61%。美國市場擁有3,600家輸液中心，並受惠於政府的報銷計劃，預計到2026年將達到76.2億美元。歐洲市場在2025年達到45.6億美元，預計2026年將達到50億美元，主要得益於波蘭和德國等國強力的報銷計畫。亞太地區市場在2025年達到25.8億美元，預計到2026年將達到28.6億美元，這主要得益於診斷技術的進步、政府的扶持政策以及日本、中國和印度等國日益增強的醫療意識。拉丁美洲和中東及非洲雖然市佔率較小，但預計將穩定成長，到2025年市場規模將分別達到7.8億美元和4億美元。

主要企業及產業趨勢

持續主導市場的主要企業包括 BioMarin、賽諾菲、艾伯維、武田製藥、輝瑞和 JCR 製藥。策略聯盟、收購和監管核准對於維持市場領先地位至關重要。主要發展動態包括：

  • 2023 年 11 月：武田製藥公司的「ADZYNMA」獲得 FDA核准用於治療先天性血栓性血小板低下紫斑症。
  • 2023 年 9 月：Amicus Therapeutics 的 Pomability + Opfolder核准FDA 批准，用於治療晚發性龐貝氏症。
  • 2021年1月：Clinigen集團的Hunterze ICV在日本獲得核准。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第4章：主要考慮因素

  • 主要疾病流行情形：依主要國家分類，2025 年
  • 新產品發布：按主要企業分類
  • 關鍵產業趨勢－併購等。
  • 新冠疫情的影響：酵素替代療法市場

第5章：2021-2034年全球酵素替代療法市場分析、洞察與預測

  • 市場分析、洞察與預測：按藥物類別分類
    • Glucosidase酶α
    • 阿加糖酶
    • 胰脂肪酶
    • 偶像硫酸酶
    • 拉羅尼酶
    • 甘油酯酶
    • α-硫酸酯酶
    • 阿斯福他酶α
    • 加硫酸酶
    • BETA-葡糖苷酶α
    • 其他
  • 市場分析、洞察與預測：按給藥途徑
    • 腸外
    • 口服
  • 市場分析、洞察與預測：按適應症分類。
    • 高雪氏症1型
    • 龐貝氏症
    • MPS（黏多醣症）
    • 外分泌性胰臟功能不全（EPI）
    • 法布瑞氏症
    • 低磷酸血症
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院
    • 居家醫療環境和靜脈輸液中心
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美酵素替代療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲酵素替代療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區酵素替代療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲酵素替代療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲酵素替代療法市場分析、洞察與預測（2021-2034年）

  • 國家
    • GCC
    • 南非
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 公司簡介
    • BioMarin
    • Leadiant Biosciences, Inc.
    • Pfizer Inc.
    • Sanofi
    • AbbVie Inc.
    • Takeda Pharmaceutical Company Limited
    • JCR Pharmaceutical Co., Ltd.
    • Nestle
Product Code: FBI106424

Growth Factors of enzyme replacement therapy (ERT) Market

The global enzyme replacement therapy (ERT) market is projected to witness robust growth in the coming years, driven by the rising prevalence of rare, chronic, and inherited disorders, along with increasing healthcare access and advanced treatment options. According to a recent market report, the global enzyme replacement therapy market size was valued at USD 15.89 billion in 2025. The market is expected to grow to USD 17.3 billion in 2026 and further reach USD 35.67 billion by 2034, exhibiting a CAGR of 9.46% from 2026 to 2034.

Enzyme replacement therapy involves the administration of specific enzymes to patients with enzyme deficiencies or related disorders. Its growing adoption is largely fueled by the prevalence of lysosomal storage disorders (LSDs) such as Gaucher disease, Fabry disease, and Pompe disease. For instance, in the United States, approximately 6,000 individuals were reported to have Gaucher disease in 2020, with 95% affected by Type 1.

Key Market Drivers

The growth of the ERT market is primarily driven by the increasing prevalence of rare disorders, continuous approvals of advanced therapy products, and improved healthcare infrastructure. Leading companies such as BioMarin, Sanofi, and Takeda Pharmaceutical Company Limited have been actively introducing innovative enzyme therapies. In July 2019, Takeda launched Idursulfase, Velaglucerase Alpha, and Agalsidase Alfa in India for treating Hunter syndrome, Gaucher disease, and Fabry disease. Furthermore, favorable reimbursement policies in developed countries and increased patient awareness are accelerating adoption rates.

During the COVID-19 pandemic, ERT experienced a positive impact due to increased sales of related drugs and the expansion of homecare initiatives for therapy administration. From 2022 onwards, rising drug sales and patient demand for advanced therapies have supported consistent market growth.

Market Segmentation Analysis

By Drug Class: In 2026, pancrelipase dominated the ERT market with a 24.13% share, primarily due to its use in treating Exocrine Pancreatic Insufficiency (EPI) among chronic pancreatitis and cystic fibrosis patients. The agalsidase segment ranked second, reflecting high costs and increasing demand for Fabry disease treatment. Collaborative initiatives, such as the 2024 partnership between mAbxience and Biosidus to produce Agalsidase Beta, are further driving growth.

By Route of Administration: The parenteral segment is expected to account for 75.87% of the market in 2026, owing to advantages like direct bloodstream delivery, consistent dosing, and suitability for patients with gastrointestinal issues. Oral administration holds a smaller share due to limited availability of oral formulations for LSDs.

By Indication: EPI held the largest share at 24.13% in 2026, supported by high prevalence rates in patients with chronic pancreatitis and cystic fibrosis. Emerging rare genetic and lysosomal disorders drive growth in the "others" category, including therapies like Brineura for Neuronal ceroid lipofuscinosis type 2.

By End User: The homecare settings & infusion centers segment is projected to grow the fastest, capturing 69.23% of the market in 2026, as patients increasingly prefer home-based treatments for convenience, cost-effectiveness, and safety. Hospitals remain important but grow at a moderate pace due to limited capacity and specialized infrastructure requirements.

Regional Insights

In 2025, North America dominated the market with USD 7.57 billion, representing 47.61% of global revenue. The U.S. market is projected to reach USD 7.62 billion in 2026, supported by 3,600 infusion centers and government reimbursement programs. Europe accounted for USD 4.56 billion in 2025 and is expected to reach USD 5 billion in 2026, with strong support from reimbursement programs in countries like Poland and Germany. Asia Pacific reached USD 2.58 billion in 2025 and is estimated at USD 2.86 billion in 2026, driven by improving diagnostics, government initiatives, and rising awareness in Japan, China, and India. Latin America and Middle East & Africa collectively held smaller market shares but are projected to grow steadily, with 2025 values of USD 0.78 billion and USD 0.4 billion, respectively.

Key Players and Industry Developments

Leading companies maintaining dominance include BioMarin, Sanofi, AbbVie Inc., Takeda, Pfizer Inc., and JCR Pharmaceuticals Co., Ltd. Strategic partnerships, acquisitions, and regulatory approvals are central to sustaining market leadership. Notable developments include:

  • November 2023: FDA approval of ADZYNMA by Takeda for congenital thrombotic thrombocytopenic purpura.
  • September 2023: FDA approval of Pombiliti + Opfolda for late-onset Pompe disease by Amicus Therapeutics.
  • January 2021: Clinigen Group obtained approval for Hunterase ICV in Japan.

Conclusion

The global enzyme replacement therapy market is poised for substantial growth between 2025 and 2034. Increasing prevalence of rare disorders, rising homecare adoption, and consistent innovations by key market players are driving the market forward. North America continues to dominate, while emerging regions in Asia Pacific show promising expansion opportunities. With enhanced regulatory approvals, reimbursement policies, and patient awareness initiatives, the market is expected to more than double by 2034, reaching USD 35.67 billion.

Segmentation By Drug Class

  • Alglucosidase alfa
  • Agalsidase
  • Pancrelipase
  • Idursulfase
  • Laronidase
  • Imiglucerase
  • Elosulfase alfa
  • Asfotase alfa
  • Galsulfase
  • Velaglucerase alfa
  • Others

By Route of Administration

  • Parenteral
  • Oral

By Indication

  • Type 1 Gaucher disease
  • Pompe Disease
  • MPS (Mucopolysaccharidosis)
  • Exocrine Pancreatic Insufficiency (EPI)
  • Fabry Disease
  • Hypophosphatasia
  • Others

By End User

  • Hospitals
  • Homecare settings & Infusion Centers

By Geography

  • North America (By Drug Class, By Route of Administration, By Indication, By End User, and By Country)
    • U.S. (By Indication)
    • Canada (By Indication)
  • Europe (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
    • U.K. (By Indication)
    • Germany (By Indication)
    • France (By Indication)
    • Italy (By Indication)
    • Spain (By Indication)
    • Scandinavia (By Indication)
    • Rest of Europe (By Indication)
  • Asia Pacific (By Drug Class, By Route of Administration, By Indication, By End User, and By Country/Sub-region)
    • Japan (By Indication)
    • China (By Indication)
    • India (By Indication)
    • Australia (By Indication)
    • Southeast Asia (By Indication)
    • Rest of Asia Pacific (By Indication)
  • Latin America (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
    • Brazil (By Indication)
    • Mexico (By Indication)
    • Rest of Latin America (By Indication)
  • Middle East& Africa (By Drug Class, By Route of Administration, By Indication, By End User, and By Country /Sub-region)
    • South Africa (By Indication)
    • GCC (By Indication)
    • Rest of Middle East & Africa (By Indication)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Key Disorders, By Key Countries/Regions, 2025
  • 4.2. New Product Launches, By Key Players
  • 4.3. Key Industry Developments - Mergers, Acquisitions, etc.
  • 4.4. Impact of COVID-19 on the Enzyme Replacement Therapy Market

5. Global Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Alglucosidase alfa
    • 5.1.2. Agalsidase
    • 5.1.3. Pancrelipase
    • 5.1.4. Idursulfase
    • 5.1.5. Laronidase
    • 5.1.6. Imiglucerase
    • 5.1.7. Elosulfase alfa
    • 5.1.8. Asfotase alfa
    • 5.1.9. Galsulfase
    • 5.1.10. Velaglucerase alfa
    • 5.1.11. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Parenteral
    • 5.2.2. Oral
  • 5.3. Market Analysis, Insights and Forecast - By Indication
    • 5.3.1. Type 1 Gaucher disease
    • 5.3.2. Pompe Disease
    • 5.3.3. MPS (Mucopolysaccharidosis)
    • 5.3.4. Exocrine Pancreatic Insufficiency (EPI)
    • 5.3.5. Fabry Disease
    • 5.3.6. Hypophosphatasia
    • 5.3.7. Others
  • 5.4. Market Analysis, Insights and Forecast - By End User
    • 5.4.1. Hospitals
    • 5.4.2. Homecare settings & Infusion Centers
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Alglucosidase alfa
    • 6.1.2. Agalsidase
    • 6.1.3. Pancrelipase
    • 6.1.4. Idursulfase
    • 6.1.5. Laronidase
    • 6.1.6. Imiglucerase
    • 6.1.7. Elosulfase alfa
    • 6.1.8. Asfotase alfa
    • 6.1.9. Galsulfase
    • 6.1.10. Velaglucerase alfa
    • 6.1.11. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Parenteral
    • 6.2.2. Oral
  • 6.3. Market Analysis, Insights and Forecast - By Indication
    • 6.3.1. Type 1 Gaucher disease
    • 6.3.2. Pompe Disease
    • 6.3.3. MPS (Mucopolysaccharidosis)
    • 6.3.4. Exocrine Pancreatic Insufficiency (EPI)
    • 6.3.5. Fabry Disease
    • 6.3.6. Hypophosphatasia
    • 6.3.7. Others
  • 6.4. Market Analysis, Insights and Forecast - By End User
    • 6.4.1. Hospitals
    • 6.4.2. Homecare settings & Infusion Centers
  • 6.5. Market Analysis, Insights and Forecast - By Country
    • 6.5.1. U.S.
      • 6.5.1.1. By Indication
    • 6.5.2. Canada
      • 6.5.2.1. By Indication

7. Europe Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Alglucosidase alfa
    • 7.1.2. Agalsidase
    • 7.1.3. Pancrelipase
    • 7.1.4. Idursulfase
    • 7.1.5. Laronidase
    • 7.1.6. Imiglucerase
    • 7.1.7. Elosulfase alfa
    • 7.1.8. Asfotase alfa
    • 7.1.9. Galsulfase
    • 7.1.10. Velaglucerase alfa
    • 7.1.11. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Parenteral
    • 7.2.2. Oral
  • 7.3. Market Analysis, Insights and Forecast - By Indication
    • 7.3.1. Type 1 Gaucher disease
    • 7.3.2. Pompe Disease
    • 7.3.3. MPS (Mucopolysaccharidosis)
    • 7.3.4. Exocrine Pancreatic Insufficiency (EPI)
    • 7.3.5. Fabry Disease
    • 7.3.6. Hypophosphatasia
    • 7.3.7. Others
  • 7.4. Market Analysis, Insights and Forecast - By End User
    • 7.4.1. Hospitals
    • 7.4.2. Homecare settings & Infusion Centers
  • 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.5.1. U.K
      • 7.5.1.1. By Indication
    • 7.5.2. Germany
      • 7.5.2.1. By Indication
    • 7.5.3. France
      • 7.5.3.1. By Indication
    • 7.5.4. Italy
      • 7.5.4.1. By Indication
    • 7.5.5. Spain
      • 7.5.5.1. By Indication
    • 7.5.6. Scandinavia
      • 7.5.6.1. By Indication
    • 7.5.7. Rest of Europe
      • 7.5.7.1. By Indication

8. Asia Pacific Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Alglucosidase alfa
    • 8.1.2. Agalsidase
    • 8.1.3. Pancrelipase
    • 8.1.4. Idursulfase
    • 8.1.5. Laronidase
    • 8.1.6. Imiglucerase
    • 8.1.7. Elosulfase alfa
    • 8.1.8. Asfotase alfa
    • 8.1.9. Galsulfase
    • 8.1.10. Velaglucerase alfa
    • 8.1.11. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Parenteral
    • 8.2.2. Oral
  • 8.3. Market Analysis, Insights and Forecast - By Indication
    • 8.3.1. Type 1 Gaucher disease
    • 8.3.2. Pompe Disease
    • 8.3.3. MPS (Mucopolysaccharidosis)
    • 8.3.4. Exocrine Pancreatic Insufficiency (EPI)
    • 8.3.5. Fabry Disease
    • 8.3.6. Hypophosphatasia
    • 8.3.7. Others
  • 8.4. Market Analysis, Insights and Forecast - By End User
    • 8.4.1. Hospitals
    • 8.4.2. Homecare settings & Infusion Centers
  • 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.5.1. Japan
      • 8.5.1.1. By Indication
    • 8.5.2. China
      • 8.5.2.1. By Indication
    • 8.5.3. India
      • 8.5.3.1. By Indication
    • 8.5.4. Australia
      • 8.5.4.1. By Indication
    • 8.5.5. Southeast Asia
      • 8.5.5.1. By Indication
    • 8.5.6. Rest of Asia Pacific
      • 8.5.6.1. By Indication

9. Latin America Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Alglucosidase alfa
    • 9.1.2. Agalsidase
    • 9.1.3. Pancrelipase
    • 9.1.4. Idursulfase
    • 9.1.5. Laronidase
    • 9.1.6. Imiglucerase
    • 9.1.7. Elosulfase alfa
    • 9.1.8. Asfotase alfa
    • 9.1.9. Galsulfase
    • 9.1.10. Velaglucerase alfa
    • 9.1.11. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Parenteral
    • 9.2.2. Oral
  • 9.3. Market Analysis, Insights and Forecast - By Indication
    • 9.3.1. Type 1 Gaucher disease
    • 9.3.2. Pompe Disease
    • 9.3.3. MPS (Mucopolysaccharidosis)
    • 9.3.4. Exocrine Pancreatic Insufficiency (EPI)
    • 9.3.5. Fabry Disease
    • 9.3.6. Hypophosphatasia
    • 9.3.7. Others
  • 9.4. Market Analysis, Insights and Forecast - By End User
    • 9.4.1. Hospitals
    • 9.4.2. Homecare settings & Infusion Centers
  • 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 9.5.1. Brazil
      • 9.5.1.1. By Indication
    • 9.5.2. Mexico
      • 9.5.2.1. By Indication
    • 9.5.3. Rest of Latin America
      • 9.5.3.1. By Indication

10. Middle East & Africa Enzyme Replacement Therapy Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Alglucosidase alfa
    • 10.1.2. Agalsidase
    • 10.1.3. Pancrelipase
    • 10.1.4. Idursulfase
    • 10.1.5. Laronidase
    • 10.1.6. Imiglucerase
    • 10.1.7. Elosulfase alfa
    • 10.1.8. Asfotase alfa
    • 10.1.9. Galsulfase
    • 10.1.10. Velaglucerase alfa
    • 10.1.11. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Parenteral
    • 10.2.2. Oral
  • 10.3. Market Analysis, Insights and Forecast - By Indication
    • 10.3.1. Type 1 Gaucher disease
    • 10.3.2. Pompe Disease
    • 10.3.3. MPS (Mucopolysaccharidosis)
    • 10.3.4. Exocrine Pancreatic Insufficiency (EPI)
    • 10.3.5. Fabry Disease
    • 10.3.6. Hypophosphatasia
    • 10.3.7. Others
  • 10.4. Market Analysis, Insights and Forecast - By End User
    • 10.4.1. Hospitals
    • 10.4.2. Homecare settings & Infusion Centers
  • 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
    • 10.5.1. GCC
      • 10.5.1.1. By Indication
    • 10.5.2. South Africa
      • 10.5.2.1. By Indication
    • 10.5.3. Rest of Middle East & Africa
      • 10.5.3.1. By Indication

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. BioMarin
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & Services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Leadiant Biosciences, Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & Services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Pfizer Inc.
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & Services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Sanofi
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & Services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. AbbVie Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & Services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. Takeda Pharmaceutical Company Limited
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & Services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. JCR Pharmaceutical Co., Ltd.
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & Services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Nestle
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & Services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 4: Global Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 5: Global Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 6: North America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 7: North America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 8: North America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 9: North America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 10: North America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 11: U.S. Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 12: Canada Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 13: Europe Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 14: Europe Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 15: Europe Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 16: Europe Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 17: Europe Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 18: Germany Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 19: U.K. Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 20: France Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 21: Italy Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 22: Spain Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 23: Scandinavia Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 24: Rest of Europe Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2033
  • Table 25: Asia Pacific Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 26: Asia Pacific Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 27: Asia Pacific Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 28: Asia Pacific Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 29: Asia Pacific Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 30: Japan Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 31: India Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 32: China Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 33: Australia Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 34: Southeast Asia Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 35: Rest of Asia Pacific Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 36: Latin America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Latin America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 38: Latin America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 39: Latin America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 40: Latin America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 41: Brazil Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 42: Mexico Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 43: Rest of Latin America Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 44: Middle East & Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 45: Middle East & Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 46: Middle East & Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 47: Middle East & Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 48: Middle East & Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 49: GCC Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 50: South Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034
  • Table 51: Rest of Middle East & Africa Enzyme Replacement Therapy Market Revenue (USD billion) Forecast, by Indication, 2021-2034

List of Figures

  • Figure 1: Global Enzyme Replacement Therapy Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Enzyme Replacement Therapy Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Enzyme Replacement Therapy Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Enzyme Replacement Therapy Market Value Share (%), by Indication, 2025 & 2034
  • Figure 5: Global Enzyme Replacement Therapy Market Value Share (%), by End User, 2025 & 2034
  • Figure 6: Global Enzyme Replacement Therapy Market Value (USD billion), by Region, 2025 & 2034
  • Figure 7: North America Enzyme Replacement Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 8: North America Enzyme Replacement Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 9: North America Enzyme Replacement Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 10: North America Enzyme Replacement Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 11: North America Enzyme Replacement Therapy Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 12: North America Enzyme Replacement Therapy Market Value Share (%), by Indication, 2025
  • Figure 13: North America Enzyme Replacement Therapy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 14: North America Enzyme Replacement Therapy Market Value Share (%), by End User, 2025
  • Figure 15: North America Enzyme Replacement Therapy Market Value (USD billion), By Country, 2025 & 2034
  • Figure 16: North America Enzyme Replacement Therapy Market Value Share (%), By Country, 2025
  • Figure 17: Europe Enzyme Replacement Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 18: Europe Enzyme Replacement Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 19: Europe Enzyme Replacement Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 20: Europe Enzyme Replacement Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 21: Europe Enzyme Replacement Therapy Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 22: Europe Enzyme Replacement Therapy Market Value Share (%), by Indication, 2025
  • Figure 23: Europe Enzyme Replacement Therapy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 24: Europe Enzyme Replacement Therapy Market Value Share (%), by End User, 2025
  • Figure 25: Europe Enzyme Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 26: Europe Enzyme Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 27: Asia Pacific Enzyme Replacement Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 28: Asia Pacific Enzyme Replacement Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 29: Asia Pacific Enzyme Replacement Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 30: Asia Pacific Enzyme Replacement Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 31: Asia Pacific Enzyme Replacement Therapy Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 32: Asia Pacific Enzyme Replacement Therapy Market Value Share (%), by Indication, 2025
  • Figure 33: Asia Pacific Enzyme Replacement Therapy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 34: Asia Pacific Enzyme Replacement Therapy Market Value Share (%), by End User, 2025
  • Figure 35: Asia Pacific Enzyme Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 36: Asia Pacific Enzyme Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 37: Latin America Enzyme Replacement Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 38: Latin America Enzyme Replacement Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 39: Latin America Enzyme Replacement Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 40: Latin America Enzyme Replacement Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 41: Latin America Enzyme Replacement Therapy Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 42: Latin America Enzyme Replacement Therapy Market Value Share (%), by Indication, 2025
  • Figure 43: Latin America Enzyme Replacement Therapy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 44: Latin America Enzyme Replacement Therapy Market Value Share (%), by End User, 2025
  • Figure 45: Latin America Enzyme Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 46: Latin America Enzyme Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 47: Middle East & Africa Enzyme Replacement Therapy Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 48: Middle East & Africa Enzyme Replacement Therapy Market Value Share (%), by Drug Class, 2025
  • Figure 49: Middle East & Africa Enzyme Replacement Therapy Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 50: Middle East & Africa Enzyme Replacement Therapy Market Value Share (%), by Route of Administration, 2025
  • Figure 51: Middle East & Africa Enzyme Replacement Therapy Market Value (USD billion), by Indication, 2025 & 2034
  • Figure 52: Middle East & Africa Enzyme Replacement Therapy Market Value Share (%), by Indication, 2025
  • Figure 53: Middle East & Africa Enzyme Replacement Therapy Market Value (USD billion), by End User, 2025 & 2034
  • Figure 54: Middle East & Africa Enzyme Replacement Therapy Market Value Share (%), by End User, 2025
  • Figure 55: Middle East & Africa Enzyme Replacement Therapy Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 56: Middle East & Africa Enzyme Replacement Therapy Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 57: Global Enzyme Replacement Therapy Market Share (%), By Company, 2025